Prolia (denosumab) / Amgen 
Welcome,         Profile    Billing    Logout  
 110 Diseases   151 Trials   151 Trials   7120 News 


«12...1516171819202122232425...8687»
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Journal:  Circulating miRNAs Respond to Denosumab Treatment after Two Years in Postmenopausal Women with Osteoporosis. (Pubmed Central) -  Apr 14, 2023   
    Two years of DMAB treatment resulted in upregulation of 7 miRNAs, 4 of which are mainly transcribed in monocytes, indicating a potential impact of DMAB on circulating osteoclast precursor cells. These changes were associated to BMD gain and BTM suppression and could therefore be useful for monitoring DMAB treatment response.
  • ||||||||||  HLX14 (denosumab biosimilar) / Fosun Pharma, Organon
    Enrollment closed, Trial completion date:  A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia (clinicaltrials.gov) -  Apr 11, 2023   
    P3,  N=478, Active, not recruiting, 
    Suspended --> Terminated; Insufficient accrual Recruiting --> Active, not recruiting | Trial completion date: Apr 2024 --> Aug 2024
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Journal:  When and how to stop denosumab therapy in a patient with osteoporosis. (Pubmed Central) -  Apr 4, 2023   
    Further studies are required to confirm safety and efficacy beyond 10 years treatment, but it is likely that patients will have ongoing benefit on therapy beyond this. We aim to present a personal perspective of why and how denosumab should be discontinued in patients with osteoporosis.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Bone disease (Grote Zaal) -  Apr 4, 2023 - Abstract #EMN2023EMN_106;    
    Radiotherapy should be considered for uncontrolled pain due to impeding or symptomatic spinal cord compression and due to pathological fractures. Surgery should be considered for prevention and restoration of long-bone pathological fractures, vertebral column instability and spinal cord compression with bone fragments within the spinal route
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Journal:  Bisphosphonates Prescription for Patients With Hip Fractures Based on Evaluation by a Dentist. (Pubmed Central) -  Mar 30, 2023   
    Surgery should be considered for prevention and restoration of long-bone pathological fractures, vertebral column instability and spinal cord compression with bone fragments within the spinal route Methods Of 180 patients with hip fractures treated surgically at our hospital between August 2019 and April 2020, 149 patients (46 men and 103 women; mean age: 83.9
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Clinical, Journal:  Loss of lower extremity bone mineral density 1 (Pubmed Central) -  Mar 30, 2023   
    Methods Of 180 patients with hip fractures treated surgically at our hospital between August 2019 and April 2020, 149 patients (46 men and 103 women; mean age: 83.9 In persons with SCI who initiated denosumab treatment during the subacute injury phase and maintained treatment for 1
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Clinical, Review, Journal:  Management of bone loss due to endocrine therapy during cancer treatment. (Pubmed Central) -  Mar 30, 2023   
    Bone modifying agents BMAs (oral and IV bisphosphonates, denosumab) are used to treat bone loss due to endocrine therapy in patients with hormone receptor positive (HR?+) early breast cancer and non-metastatic prostate cancer (NMPC)...Due to limited data in cancer patients regarding management of osteoporosis, a dosing schedule similar to osteoporosis is considered appropriate. Risk stratification to identify vulnerable patient population, choosing the appropriate sequential therapy, and close monitoring of patients at the risk of bone loss can potentially reduce the mortality, morbidity, and health care cost related to CTIBL.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Review, Journal, HEOR, Cost-effectiveness, Cost effectiveness:  A systematic review of cost?effectiveness analyses of sequential treatment for osteoporosis. (Pubmed Central) -  Mar 30, 2023   
    Generally, the sequential treatments involving abaloparatide, romosozumab, denosumab, and bisphosphonates may be considered as the preferred option for osteoporosis with high fracture risk, while the sequential treatment with teriparatide was not a cost-effectiveness strategy. The ESCEO-IOF and CHEER (2022) increase the transparency, comparability, extrapolation, and quality of research, engage patients and the general public in research on health services and policies, and help improve the quality of health technology assessment.
  • ||||||||||  ATI-2231 / Aclaris
    New P1 trial, New P1/2 trial, Combination therapy, Metastases:  ATI-2231 in Advanced Solid Tumor Malignancies (clinicaltrials.gov) -  Mar 30, 2023   
    P1/2,  N=174, Not yet recruiting, 
  • ||||||||||  Prolia (denosumab) / Amgen, Keytruda (pembrolizumab) / Merck (MSD)
    Enrollment closed, Trial completion date, Trial primary completion date:  KEYPAD: Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma (clinicaltrials.gov) -  Mar 29, 2023   
    P2,  N=59, Active, not recruiting, 
    The ESCEO-IOF and CHEER (2022) increase the transparency, comparability, extrapolation, and quality of research, engage patients and the general public in research on health services and policies, and help improve the quality of health technology assessment. Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Jun 2023 | Trial primary completion date: Dec 2022 --> Jun 2023
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, Lutathera (lutetium Lu 177 dotatate) / Novartis
    How I Net the Bronchus: The Carcinoid Tumors of the Airway: A Case Report (Walter E. Washington Convention Center, Area L, Hall C (Lower Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_7825;    
    She was further treated octreotide, denosumab, and lutetium Lu 177 dotatate...Repeat bronchoscopy has demonstrated successful reduction of carcinoid tumor and lack of complications such as bronchial stenosis.Cryotherapy can be a powerful adjunctive treatment for metastatic bronchial carcinoid tumors. It is generally a safe procedure with limited side effect profile, including lack of association with long-term bronchial stenosis.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    A Man With Palbociclib-Induced Pneumonitis: A Very Rare Entity (Walter E. Washington Convention Center, Room 103 A-B (Street Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_3515;    
    He was receiving his second cycle of palbociclib along with letrozole, leuprolide and denosumab...He was initially treated for community acquired pneumonia with ceftriaxone and azithromycin...Palbociclib was also discontinued. Bronchoscopy may not always be needed to confirm or excluded other pathology in the appropriate clinical context especially in severe cases.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Review, HEOR, Cost-effectiveness, Cost effectiveness:  Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review. (Pubmed Central) -  Mar 24, 2023   
    Screening strategies and post-fracture care programs also showed economic benefits for men. Cost-effectiveness and intervention thresholds were generally similar in studies conducted in both men and women, with slightly greater incremental cost-effectiveness ratios in men.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, Evenity (romosozumab) / Astellas, Amgen, UCB
    Journal:  Osteoporosis: Common Questions and Answers. (Pubmed Central) -  Mar 20, 2023   
    Patients at high risk of fracture should consider treatment with antiresorptive therapy, including bisphosphonates and denosumab. Anabolic agents such as teriparatide, abaloparatide, and romosozumab should be considered for patients at very high risk or with previous vertebral fractures.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Journal, Real-world evidence, Real-world:  An Evaluation of Treatment Patterns for Osteoporosis and Outcomes Following a Fragility Fracture in a Real-world Setting. (Pubmed Central) -  Mar 20, 2023   
    Anabolic agents such as teriparatide, abaloparatide, and romosozumab should be considered for patients at very high risk or with previous vertebral fractures. Low rates of osteoporosis testing and treatment initiation and high secondary fracture rates (particularly among patients at very high risk) highlight the need for better management of patients after a fracture.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Journal:  Giant Cell Tumor of Bone Without Giant Cells with a Long Clinical Course: A Case Report. (Pubmed Central) -  Mar 15, 2023   
    Other unusual findings in GCTB that were identified in this patient include bone and osteoid formation with a long clinical course of 13 years. We also compared the histological findings of the current patient to those who received denosumab therapy.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Journal:  Clinical and Radiographic (Pubmed Central) -  Mar 15, 2023   
    No major complications after implant placement under antiresorptives could be detected. As long as implant surgery follows a specific protocol, implant placement in patients treated with antiresorptive therapy seems to be safe and predictable.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Enrollment change, Trial withdrawal:  Denosumab and Screw Fixation for Osteoporotic Compression Fracture (clinicaltrials.gov) -  Mar 14, 2023   
    P2/3,  N=0, Withdrawn, 
    The manifold effects of zoledronic acid and denosumab on cancer cells remain to be studied in more detail. N=125 --> 0 | Recruiting --> Withdrawn
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Journal:  Osteoporosis Treatment: Decreased Mortality Too? (Pubmed Central) -  Mar 13, 2023   
    Risk-based treatment decisions may allow for more appropriate medication selection. No abstract available